Core Viewpoint - The company Wangshan Wangshui-B (02630.HK) has entered into a licensing agreement with Xiansheng Pharmaceutical (02096.HK) for the new indications of VV116, focusing on respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections in Greater China [1] Group 1 - The licensing agreement grants Xiansheng Pharmaceutical exclusive rights to develop and commercialize VV116 for RSV and HMPV indications in the Greater China region [1] - The collaboration aims to leverage the strengths of both companies in research and development, production, and commercialization to accelerate the clinical development and commercialization process of VV116 [1] - The partnership is expected to benefit a larger patient population by enhancing the availability of VV116 for treating RSV and HMPV infections [1]
旺山旺水-B(02630.HK)与先声药业就氢溴酸氘瑞米德韦(VV116)新适应症订立许可协议